z-logo
open-access-imgOpen Access
Processing of 60,000-dalton sarc gene protein synthesized by cell-free translation.
Author(s) -
James Kamine,
John M. Buchanan
Publication year - 1978
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.75.9.4399
Subject(s) - rous sarcoma virus , reticulocyte , translation (biology) , biology , cell free system , protein biosynthesis , vesicle associated membrane protein 8 , microbiology and biotechnology , signal peptide , integral membrane protein , immunoprecipitation , biochemistry , membrane protein , group specific antigen , rna , messenger rna , peptide sequence , gene , membrane , in vitro
In this report we show that antiserum prepared against the Mr60,000 transformation-specific antigen of Rous sarcoma virus immunoprecipitates both the Mr60,000 and Mr 25,000 transformation-specific proteins that are synthesized by cell-free translation of virion RNA; however, in the cell-free system the Mr 60,000 protein appears to be synthesized as a precursor that is approximately Mr 2000 larger than the [35S]-methionine-labeled protein immunoprecipitated from Rous sarcoma virus-infected cells. Peptide mapping of the cell-free translation product and of this cellular protein has confirmed that they are structurally related to one another. The addition of membrane vesicles to the reticulocyte lysate system during translation specifically cleaves a Mr 2000 segment from the Mr 60,000 protein so that it comigrates with the cellular species. Secretory proteins and probably at least some integral membrane proteins are synthesized with short hydrophobic signal sequences at their NH2 terminus. Two facts suggest that the segment lost from the Mr 60,000 transformation-specific protein is a signal sequence: (i) the membrane vesicles process the Mr 60,000 protein only during translation, and (ii) the processed protein is sequestered by the vesicles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here